HCG Launches India’s First EDGE Multi-Port Endoscopic Surgical Robot System to Advance AI-Driven Cancer Care

Its AI-powered imaging algorithm and fluorescence-guided visualization technology are designed to help surgeons identify tissues with greater clarity during procedures, enhancing surgical precision.

HCG has introduced India’s first EDGE Multi-Port Endoscopic Surgical Robot System, expanding its portfolio of AI-powered imaging and robotic-assisted surgical technologies aimed at improving precision, control, and patient outcomes in complex procedures.

The system combines AI-driven imaging algorithms with advanced fluorescence imaging modes and upgraded ergonomics designed to support minimally invasive surgeries across multiple specialities.

Founded in 1989 and headquartered in Bengaluru, HCG has grown into one of India’s largest cancer care networks. HCG currently operates 21 cancer centres, four multispecialty hospitals, and eight day care centres across the country, while also maintaining an international presence in Kenya.

Over the years, the physician-led organisation has focused on centralising oncology services to improve access to specialised treatment and long-term patient care.

The newly launched EDGE Multi-Port Endoscopic Surgical Robot System is expected to strengthen HCG’s clinical capabilities in minimally invasive procedures.

The platform offers more than 30 specialised instruments tailored for different medical disciplines.

Its AI-powered imaging algorithm and fluorescence-guided visualization technology are designed to help surgeons identify tissues with greater clarity during procedures, while improved ergonomics aim to enhance surgical precision and operational control.

The development aligns with HCG’s broader expansion and technology strategy announced earlier this year.

HCG recently revealed plans to add nearly 1,000 beds over the next five years, increasing its total capacity from approximately 2,500 to around 3,500 beds. The expansion will include both greenfield hospital projects and capacity additions at existing centres.

HCG is currently evaluating growth opportunities across several tier-II and metro markets, including Pune, Surat, Kolkata, Guwahati, Hyderabad, Chennai, and Coimbatore as part of its next phase of growth.

Backed by private equity firm KKR, the company has also indicated that it remains open to mergers and acquisitions involving standalone oncology centres and regional hospital chains.

HCG has stated that it plans to invest nearly INR 200-250 Cr annually while continuing to focus on operational efficiency and long-term margin improvement.

Stay tuned for more such updates on Digital Health News